Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.

ABSTRACT:

Importance

The immunopathogenic mechanisms of dry eye disease (DED), one of the most common ophthalmic conditions, is incompletely understood. Data from this prospective, double-masked, randomized trial demonstrate that targeting interleukin 1 (IL-1) by topical application of an IL-1 antagonist is efficacious in significantly reducing DED-related patient symptoms and corneal epitheliopathy.

Objective

To evaluate the safety and efficacy of treatment with the topical IL-1 receptor antagonist anakinra (Kineret; Amgen Inc) in patients having DED associated with meibomian gland dysfunction.

Design and setting

Prospective phase 1/2, randomized, double-masked, vehicle-controlled clinical trial.

Participants

Seventy-five patients with refractory DED.

Interventions</

SUBMITTER: Amparo F 

PROVIDER: S-EPMC4167802 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature